Rare diseases were once viewed as “small-population, small-market” conditions. Today, this perception is being reshaped by evolving global regulatory policies and market dynamics.From FDA orphan dru...
Oncology remains one of the most active areas in global clinical development. As we move into the first half of 2026, however, industry attention is shifting. The key question is no longer simply whet...
What started with rare and genetically defined diseases is now expanding rapidly into broader indications, including cardiovascular disease, metabolic disorders, obesity, complement-mediated kidney di...
When an innovative therapy aiming for a "one-time cure" is still evaluated by traditional standards that measure "months of survival," its failure may have been predetermined. In 2...
Exciting news for global biopharma companies! China's NMPA is proposing to slash clinical trial review times from 60 to just 30 working days for novel medicines – a game-changing development that...
